What Is Multicentric Castleman Disease?

If your immune system had a “group chat,” your lymph nodes would be the moderatorsscreening messages (germs), kicking out
spam (abnormal cells), and calling in backup when trouble shows up. Multicentric Castleman disease (MCD) is what happens
when that moderation system goes into overdrive in multiple places at once. The result can look like a stubborn flu that
won’t quit, plus swollen lymph nodes, inflammation, and sometimes organ stress.

MCD is rare, complicated, and often misunderstood. But the good news is that modern treatmentespecially therapies that calm
the immune system’s “too loud” signalshas made outcomes significantly better than they used to be. This article explains what
MCD is, how it differs from other forms of Castleman disease, what symptoms to watch for, how doctors diagnose it, and which
treatments are commonly used today.

Castleman disease, explained like you’re busy

“Castleman disease” isn’t one single illness. It’s a group of disorders where lymph nodes grow abnormally and the immune system
becomes dysregulated. There are two major patterns:

• Unicentric Castleman disease (UCD): one lymph node region is involved (more localized).
• Multicentric Castleman disease (MCD): multiple lymph node regions are involved (systemic, body-wide effects).

Think of UCD as one neighborhood having a noisy alarm system. MCD is when alarms are blaring across the cityeveryone’s tired,
emergency services are overwhelmed, and you can’t ignore it.

Why “multicentric” matters (and why symptoms can feel all over the place)

In MCD, immune activation happens in multiple lymph node groups and can spill into the bloodstream, causing widespread
inflammation. A major reason this gets intense is cytokineschemical messengers immune cells use to communicate.
One cytokine, interleukin-6 (IL-6), is especially important in many cases. When IL-6 (and other signals) run high,
people may develop fever, fatigue, night sweats, weight loss, anemia, low albumin, fluid retention, and enlarged organs like the
spleen.

Doctors sometimes describe severe MCD as “cytokine-driven,” meaning the illness isn’t just about bigger lymph nodesit’s about
a body-wide inflammatory cascade that can affect blood counts, kidneys, liver function, and more.

Types of multicentric Castleman disease

MCD is typically grouped based on what’s driving it. Understanding the type matters because treatment choices often depend on it.

1) HHV-8–associated MCD

Some cases are linked to human herpesvirus 8 (HHV-8) (also called KSHV). This form is more common in people with
immune suppressionclassically those living with HIV, though it can occur in others with weakened immunity. HHV-8 can
push immune cells to produce inflammatory signals (including IL-6-related pathways), driving systemic symptoms and lymph node
changes.

2) Idiopathic MCD (iMCD)

“Idiopathic” means the exact cause isn’t known. In idiopathic multicentric Castleman disease (iMCD), HHV-8 is not the driver,
and doctors must rule out other conditions that can mimic it (like certain cancers, autoimmune diseases, and infections).

iMCD isn’t one-size-fits-all. Some people have milder disease that’s mainly fatigue and labs out of range. Others have severe
inflammation with fluid overload and organ dysfunction. One recognized clinical pattern is TAFRO syndrome (a constellation
that may include thrombocytopenia, anasarca/edema, fever, reticulin fibrosis, and organ enlargement). Not everyone with iMCD has
TAFRO features, but the term comes up in specialty discussions.

3) POEMS-associated MCD

MCD can also appear alongside POEMS syndrome, a rare plasma cell disorder. POEMS is known for features such as neuropathy
(nerve problems), endocrine changes, and other systemic findings. When POEMS is involved, treatment may target the underlying plasma
cell disease as well as the inflammatory symptoms.

Common symptoms and signs of MCD

Because MCD is systemic, symptoms can be a mix of “flu-like,” inflammatory, and organ-related issues. Some of the most commonly
reported include:

• Enlarged lymph nodes in multiple areas (neck, armpits, chest, abdomen, groin)
• Fever and night sweats
• Fatigue that feels disproportionate (the “I slept 10 hours and still feel hit by a truck” vibe)
• Unintentional weight loss or reduced appetite
• Swelling in legs or abdomen, or generalized fluid retention
• Shortness of breath (sometimes related to fluid overload or anemia)
• Enlarged spleen or liver in some cases
• Skin changes or neuropathy more often when POEMS is part of the picture

What bloodwork can look like

MCD often triggers lab abnormalities that reflect inflammation and immune activation. Doctors may see:

• Elevated CRP or ESR (markers of inflammation)
• Anemia (low red blood cells)
• Low albumin (a protein made by the liver; low levels can link to swelling)
• Abnormal platelets (either low or high, depending on subtype and severity)
• Polyclonal hypergammaglobulinemia (higher antibody levels in some iMCD cases)
• Kidney or liver test changes if organs are affected

What causes MCD?

The “why” depends on the type:

• HHV-8–associated MCD: Viral-driven immune activation is central. Risk is higher with immune suppression.
• iMCD: The exact trigger is unknown. Leading theories include abnormal immune regulation (auto-inflammatory or autoimmune
  patterns), paraneoplastic mechanisms (signals from abnormal cell populations), or an infection trigger that isn’t HHV-8. The common
  endpoint is often a cytokine surgeespecially IL-6in many patients.
• POEMS-associated MCD: The underlying plasma cell disorder is a major driver.

One helpful way to think about MCD is: it’s less about one germ you “caught” and more about the immune system getting stuck in a
high-alert setting it can’t turn off without help.

How doctors diagnose multicentric Castleman disease

Diagnosing MCD can take time because symptoms overlap with many more common conditions. Clinicians typically combine:
imaging, lab patterns, andmost importantlya lymph node biopsy.

Step 1: Confirm multicentric lymph node involvement

Imaging (such as CT or PET/CT) can show multiple enlarged lymph node regions and help evaluate spleen or liver enlargement.
Imaging alone can’t confirm MCD, but it helps map what’s going on and guides biopsy decisions.

Step 2: Lymph node biopsy (the centerpiece of diagnosis)

A biopsy lets pathologists examine lymph node architecture under the microscope. Castleman disease has characteristic patterns
(often described with terms like hyaline vascular, plasmacytic, or mixed features). The biopsy also helps exclude lymphoma and other
cancersan essential part of the workup.

Step 3: Identify the type and rule out look-alikes

Doctors test for HHV-8 and typically evaluate for HIV, since HHV-8–associated MCD frequently overlaps with immune
suppression. For iMCD, diagnosis requires meeting specific criteria and excluding mimicking conditions. These mimics may include:

• Hodgkin or non-Hodgkin lymphoma
• Autoimmune diseases (some can cause lymph node changes plus inflammation)
• Chronic infections or inflammatory disorders
• Other rare immune dysregulation syndromes

A practical snapshot of iMCD diagnostic thinking

Specialty criteria for iMCD generally require (1) characteristic lymph node histopathology and (2) enlarged lymph nodes in multiple
regions, plus a set of supporting clinical/lab features, and (crucially) careful exclusion of other diseases that can imitate iMCD.

In real life, this means a hematologist may say something like: “Your biopsy looks consistent, your nodes are multicentric, your labs
show significant inflammation, and we’ve ruled out the main alternativesso iMCD fits best.”

Treatment options for MCD

Treatment depends on the type (HHV-8 vs iMCD vs POEMS-associated) and how severe the disease is. Most patients benefit from care
at (or in consultation with) a hematology center familiar with Castleman disease, because management can be nuanced.

iMCD: Targeting IL-6 (often first-line)

For many people with iMCD, treatment focuses on calming cytokine signalingespecially IL-6. The most well-known IL-6–targeting
therapy is siltuximab, an anti–IL-6 monoclonal antibody that is widely recognized as a first-line option for non–HHV-8 iMCD.
If siltuximab isn’t available or appropriate, tocilizumab (an IL-6 receptor blocker) may be considered in some settings.

These medications are typically given by infusion (or injection, depending on the drug and plan) and require monitoring for response
over time. Improvement may show up as better energy, reduced fevers/sweats, shrinking lymph nodes, improved anemia, and lower CRP.

HHV-8–associated MCD: Rituximab-based therapy

In HHV-8–associated MCD, a cornerstone treatment is often rituximab, a medication that targets CD20-positive B cells. It can be
highly effective, and some patients may also require additional approaches such as antivirals and/or chemotherapy, depending on disease
severity and response.

Because HHV-8 MCD is frequently intertwined with immune status, the overall plan may also include optimizing HIV therapy when relevant,
managing infections proactively, and close follow-up for relapse risk.

When steroids show up in the plan

Corticosteroids can reduce inflammation quickly and may help stabilize symptoms short-term. But steroids are usually not an ideal
long-term solo strategy in iMCD, because symptoms can rebound when tapering. They’re often used as a bridge while longer-acting therapies
take effect, or as part of combination regimens in more severe cases.

Other treatments that may be considered

When IL-6–directed therapy isn’t enoughor when disease is severespecialists may use additional options, tailored to the patient’s type and
clinical picture:

• Immunomodulators (in select cases) to calm immune activation
• Chemotherapy (more common in aggressive or refractory situations, or in HHV-8 MCD with severe disease)
• Supportive care such as diuretics for fluid overload, treatment of anemia, and nutritional support
• POEMS-directed therapy when POEMS syndrome is the driver

Prognosis and long-term monitoring

Prognosis varies widely because MCD isn’t a single uniform disease. Some people respond well to targeted therapy and live with long-term
disease control. Others may have relapsing or treatment-resistant illness that requires multiple lines of therapy.

Long-term monitoring often includes periodic symptom review, physical exams, inflammatory markers (like CRP), blood counts, metabolic panels,
and imaging when clinically needed. The goal is to confirm remission, spot relapse early, and manage side effects of treatment.

When to seek urgent medical care

MCD can become serious, especially during inflammatory flares. Seek urgent care if you have symptoms such as:

• High fever with worsening weakness or dehydration
• New or worsening shortness of breath
• Rapid swelling, sudden weight gain from fluid, or severe abdominal swelling
• Confusion, fainting, or severe chest pain

These symptoms don’t automatically mean MCD is the causebut they do mean you need prompt medical evaluation.

Questions to ask your healthcare team

• Do my biopsy findings fit Castleman disease, and what subtype do you suspect?
• Have HHV-8 and HIV been evaluated, and what do the results mean for treatment?
• Which lab markers will we track to measure response (CRP, hemoglobin, albumin, others)?
• Is IL-6–directed therapy appropriate for me, and what response timeline should we expect?
• What side effects should I watch for, and when should I call you urgently?
• Should I be seen at (or consult with) a center experienced in Castleman disease?

Conclusion

Multicentric Castleman disease is a rare immune disorder where multiple lymph node regions become overactive and trigger systemic inflammation.
The details matter: HHV-8–associated MCD, idiopathic MCD, and POEMS-associated MCD can look similar on the surface but often require different
treatment strategies. Diagnosis usually hinges on a lymph node biopsy plus supportive clinical and lab features and exclusion of mimicking conditions.
Treatment has advanced significantly, with IL-6–directed therapies commonly used for iMCD and rituximab-based approaches often used for HHV-8–associated
disease.

If you’re navigating symptoms, testing, or a new diagnosis, you’re not aloneand you’re not being “dramatic” if your body feels like it’s running a marathon
while you’re just trying to make breakfast. With the right workup and specialty care, many patients find a plan that brings inflammation under control and helps
them get their life back.

Real-world experiences with multicentric Castleman disease (what people often describe)

The experience of MCD often starts with something frustratingly ordinary: fatigue, low-grade fevers, night sweats, or weight loss that gets blamed on stress,
“a virus,” or a busy schedule. Many people describe a phase where they know something is wrong, but every test comes back just vague enough to be unhelpful.
Inflammation markers may be high, blood counts may drift down, and the body can feel like it’s stuck in a permanent sick daywithout the courtesy of a clear
explanation.

A common theme is the diagnostic “pinball machine.” Patients bounce between primary care, urgent care, infectious disease workups, and sometimes rheumatology.
Imaging might finally show enlarged lymph nodes in more than one area, which can be scary because it raises the question of lymphoma. That fear is realand
many people describe the waiting period for biopsy results as the hardest part emotionally. Once a lymph node biopsy is done, the words “Castleman disease” may
feel like both relief and confusion at the same time: relief because it’s an answer, confusion because almost nobody has heard of it.

When treatment begins, people’s day-to-day stories diverge based on subtype and severity. Some describe IL-6–targeting therapy as the first time in months
(or years) that the “constant flu feeling” starts to liftsleep improves, appetite returns, and the crushing fatigue becomes more manageable. Others describe a
slower response, with improvement measured in lab trends and small wins: walking a bit farther, needing fewer naps, or seeing swelling reduce. For those on
rituximab-based therapy (often in HHV-8–associated MCD), the experience can include careful scheduling, infection precautions, and frequent follow-ups to track
symptoms and viral activity.

People also talk about the practical side that doesn’t show up in a lab report: planning around infusion days, negotiating time off school or work, and explaining
an “invisible illness” to friends who assume you look fine. Many patients describe learning a new vocabularyCRP, IL-6, albumin, anemiaand using it to advocate
for themselves. Some keep a symptom journal to connect the dots between flares, stress, sleep, and medications. Caregivers often describe their own learning curve:
figuring out which symptoms are urgent, how to help with appointments, and how to support someone whose energy can change dramatically week to week.

One of the most repeated “I wish I knew this sooner” messages is that MCD management often improves when a specialist familiar with Castleman disease is involved.
Even if care stays local, a consult can help confirm subtype, align treatment with consensus guidance, and reduce trial-and-error. Many people find community through
rare disease organizations and patient networksplaces where they don’t have to start every conversation with a five-minute explanation of what their diagnosis is.
The emotional arc is real: fear at the beginning, cautious optimism with treatment, and then a long-term mindset of monitoring, adjusting, and celebrating stable
stretches. It’s not always linear, but many patients describe progress that starts with one important step: finally being believed, thoroughly evaluated, and treated
with a plan that matches the biology of their disease.

SEO Tags